Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

Area of Science:

• Immunology
• Oncology
• Cancer Therapy

Background:

• Programmed death-1 receptor (PD-1) engagement on T cells suppresses immune responses.
• Tumor cells exploit immune checkpoints like PD-1 to evade immune surveillance.
• Regulatory T cells (Tregs) contribute to immune suppression within the tumor microenvironment.

Purpose of the Study:

• To investigate the synergistic effects of combining an anti-PD-1 antibody (CT-011), cyclophosphamide (CPM)-mediated Treg depletion, and a tumor vaccine.
• To elucidate the mechanisms underlying the combined therapeutic approach's efficacy.
• To evaluate the impact on antigen-specific immune responses and tumor regression.

Main Methods:

• Treatment of tumor-bearing animals with a combination of anti-PD-1 antibody (CT-011), low-dose cyclophosphamide (CPM), and a tumor vaccine.
• Analysis of tumor-infiltrating lymphocytes, including CD8(+) T cells and Treg cells.
• Assessment of immune responses and survival rates.

Main Results:

• The combination therapy induced synergistic antigen-specific immune responses, leading to complete regression of established tumors in a significant percentage of animals.
• CT-011 prolonged CPM-induced Treg suppression, resulting in a sustained decrease in both splenic and tumor-infiltrated Treg cells.
• The anti-tumor effect was dependent on both CD8(+) and CD4(+) T-cell responses, despite the use of a class I MHC-restricted peptide antigen.
• Survival was significantly prolonged in the treated group.

Conclusions:

• Combining anti-PD-1 antibody therapy, Treg depletion with CPM, and tumor vaccination represents a novel and effective therapeutic strategy.
• This approach targets multiple immune inhibitory mechanisms, enhancing anti-tumor immunity.
• The combination therapy demonstrates significant potential for treating established tumors.